Author: Ravi Shankar

Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris:

Abstract Title:	AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease
Presenting Author:	Guillermo J. Valenzuela, M.D., F.A.C.R. Medical Director, Integral Rheumatology & Immunology Specialists
Session:	Breaking news from clinical trials
Date/Time/Location:	Thursday, October 1, 2026 at 4:30 – 6:00 pm CEST, Amphitheater Adenauer

For more information on this and other abstracts, please visit the ISSjD 2026 abstract book.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK^® (also known as AB-101), in refractory rheumatoid arthritis (RA) in the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity for a range of antibodies, including anti-CD20 antibodies, and drive deep B-cell depletion. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases, together with a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK to drive deep B-cell depletion through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the potential benefits, accessibility, practicality, effectiveness, safety and tolerability of AlloNK, including based on interim pooled data across clinical trials, and the potential for administration in an outpatient community setting; the registrational Phase 3 trial for AlloNK, including trial design, expectations for response rates, and timing of initiation, future updates on site activation and enrollment, and topline data readout; and Artiva’s ability to generate sufficient data to support a BLA submission; clinical data expected to be available and presented in refractory RA, SjD and SSc, and the timing of such data disclosures; the number of patients with data from the basket study who would be expected to meet the key eligibility criteria for the planned Phase 3 trial; Artiva’s ability to realize the potential benefits associated with FDA RMAT designation for AlloNK; Artiva’s beliefs regarding its competitive position, including its belief that AlloNK may be the first deep or deep B-cell depleting therapy of any modality to reach patients with, and be approved and commercialized in, refractory RA; and Artiva’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks and delays relating to initiation of the Phase 3 registrational trial, activation of clinical trial sites, patient enrollment and the availability and timing of disclosure of data; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials, or with Artiva’s expectations; the risk that the number of patients, or the duration of follow-up for such patients, available for presentation differs from current expectations; the risk that differences exist between trial designs, patient characteristics and other factors for the Phase 3 trial, Artiva-sponsored Phase 2a basket trial and investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; the risk that other deep B-cell depleting therapies may advance more rapidly than Artiva currently anticipates, that Artiva’s assessment of publicly disclosed competitor development timelines may be incomplete or inaccurate, and that Artiva may not achieve or be the first to achieve regulatory approval or commercialization of a therapy in this category; the risk that Artiva’s registrational strategy is based in part on recent interactions with the FDA and later feedback from the FDA may be inconsistent with past interactions; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks inherent in developing product candidates; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Source: Artiva Biotherapeutics, Inc.

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce that it has entered into an option agreement (the “Option Agreement”) with McKnight Resources AB (“McKnight”), an arm’s length party, pursuant to which McKnight has granted to Brixton the sole, exclusive and irrevocable right and option (the “Option”) to acquire an undivided 100% interest in and to certain mineral exploration permits located in Hällefors Municipality, Örebro County, south central Sweden, commonly known by the names “Silvergruvan 100” and “Silvergruvan 200” (collectively, the “Silvergruvan Property”). The Option Agreement remains subject to the receipt of acceptance from the TSX Venture Exchange (the “TSXV”). No finder’s fees are payable in connection with the Option.

The Silvergruvan Property comprises 1,460 hectares and is prospective for silver, gold, lead, zinc, antimony and indium. The Silvergruvan Property saw historical mining activity spanning from the 1600s to the late 20^th century and sits on the western margin of the Bergslagen province, placing the property in immediate proximity to major active polymetallic operations. Silvergruvan shares similar geology to major silver-lead-zinc deposits like Garpenburg⁽¹⁾, Sala, and Zinkgruvan⁽¹⁾ in the region.

Chairman and CEO Gary R. Thompson, stated: “The Silvergruvan Property represents an attractive opportunity for new discoveries in a region that has not seen much modern exploration, yet it shares similar geology to Garpenburg, one of the world’s most productive underground zinc mines. In 2025, Boliden stated most of this mine’s revenue was from silver and is a long-life mine with deep rooted mineralization where mining reaches 1,500 meters depth and remains open.” ^(1,2)

According to Boliden, in 2025, the most valuable commodity for Garpenberg was silver. Silver accounted for 47% of the revenue, followed by zinc 32%, gold at 11%, lead at 10% and copper at less than 1%.⁽²⁾

Silvergruvan History

1635 – silver first discovered.⁽³⁾

Tumi Resources (news release, May 15, 2008) stated, ” No production figures are available for the eastern silver mines, but during 1878-1896 and 1915-1917, 9,000 tonnes were produced from the western silver mines grading approximately 1,560 g/t Ag, 12% Zn and 38% Pb. Records indicate that between 1639 and 1852, Hällefors produced just over 480,000 oz of silver…”.

1892 – From the report, “The Minerals of the Silver Mines of Hällefors”, the average grade of ore from the western fields was 0.156% Ag. In the years of 1639 – 1852, the silver-bearing ore mined was 15 tons.⁽⁴⁾

1977 – Boliden restarts underground mining at eastern fields.

1997 – Boliden forms JV with Lundin Group and drills 2,000 meters at western fields.

2008 – Tumi Resources forms JV with Goldsearch; conducts EM survey, no drilling.

2026 – McKnight acquired Silvergruvan through staking.

2026 – Rock grab samples collected by McKnight with assays in Figure 1 (below).

Figure 1. Select rock grab sample photographs/assays from the Silvergruvan Property 2026.

Sixteen waste dump rock grab samples from the Silvergruvan Project were collected by McKnight and of these; 9 samples were greater than 200 g/t silver including 6 were greater than 500 g/t silver with a high of 800 g/t silver; 5 samples returned greater than 1 g/t gold with a high of 1.8 g/t gold; 8 samples returned greater than 5% lead with a high of 18.4% lead; 8 samples returned greater than 5% zinc with a high of 20.90% zinc; 5 samples returned greater than 1000 ppm antimony with a high of 1480 ppm antimony; and 4 samples returned greater than 100 ppm indium with a high of 188 ppm indium.

Infrastructure and Logistics

The Silvergruvan Property location has year-round heavy vehicle road access, excellent proximity to the national industrial power grid, and an experienced local mining workforce.

Current Mineral Resources

No mineral resource statement has been calculated at the Silvergruvan Property in modern times.

Transaction Highlights

Brixton may exercise the Option on completion of the following:

Date	Share Issuances(*)		Exploration Expenditures
On or before the 1st anniversary of the Option effective date	$150,000		$300,000
On or before the 2nd anniversary of the Option effective date	$250,000		$1,000,000
On or before the 3rd anniversary of the Option effective date	$500,000		$2,000,000
Any time following completion of the above Share issuances and exploration expenditures	$600,000
TOTAL	$1,500,000		$3,300,000

(*) Any common shares in the capital of the Company (the “Shares”) issued pursuant to the Option Agreement shall have an issue price, as and when issued, equal to the 20-day volume weighted average trading price of the Shares on a recognized stock exchange in Canada on which the Shares are then listed, such price being based on the 20 trading days preceding the date the Company elects to issue such Shares; provided, however, that the issue price shall not be less than $0.50 being the ‘Discounted Market Price’ of Shares on the TSXV as of the date of this news release.

Upon Brixton exercising the Option, it shall grant a 2.0% net smelter returns royalty (the “Royalty”) on the Silvergruvan Property in favour of McKnight, subject to a right at any time to reduce the Royalty to 1.0% by paying $1,500,000 or issuing Shares equal to $1,500,000, such Shares shall have an issue price, as and when issued, equal to the 20-day volume weighted average trading price of the Shares on a recognized stock exchange in Canada on which the Shares are then listed, such price being based on the 20 trading days preceding the date the Company elects to issue such Shares; provided, however, that the issue price shall not be less than $0.50 being the ‘Discounted Market Price’ of Shares on the TSXV as of the date of this news release.

All Share issuances and exploration expenditures are at the discretion of Brixton. Brixton may make up any shortfall in exploration expenditures for a period by making a cash payment to McKnight before the end of such period. Brixton may also accelerate the Option by making any Share issuances and exploration expenditures within a shorter period of time. Brixton shall act as operator during the Option period.

All Shares issued pursuant to the Option Agreement and Royalty will be subject to a hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. In addition, each tranche of Share issuance under the Option Agreement will be subject to a voluntary lock-up subject to a release schedule of 25% on issuance, 25% four months from the date of issuance, 25% eight months from the date of issuance and 25% twelve months from the date of issuance.

Reference Sources and Links
⁽¹⁾ https://www.boliden.com/operations/mines/boliden-garpenberg/
⁽¹⁾ https://www.boliden.com/operations/mines/boliden-zinkgruvan/
⁽²⁾ Mineral Resources and Mineral Reserves Garpenberg 2025-12-31 (click link)
⁽³⁾ History of Mines in Sweden (click link)
⁽⁴⁾ Nils Sundius, Alexander Parwel and Benita Rajandi, Geological Survey of Sweden: “The Minerals of the Silver Mines of Hällefors”, 1966.

Qualified Person (QP)

Mr. Gary Thompson, P.Geo., is the Chairman and CEO and a senior geologist for the Company who is a ‘Qualified Person’ as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Thompson has reviewed and approved the technical information presented herein. The QP conducted a site visit on August 25, 2026 and considers Silvergruvan a property of merit and recommends further exploration. Further, the QP has not completed sufficient work on the historical data to confirm the accuracy of the information provided, and there is no certainty that further exploration will result in a mineral resource.

About Brixton Metals Corporation

Brixton is a Canadian exploration company focused on the advancement of its mining projects. Brixton wholly owns four exploration projects: Brixton’s flagship Thorn copper-gold-silver-molybdenum project, the Langis and Hudson Bay silver projects in Ontario, the Hog Heaven copper silver-gold project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc., and the Atlin Goldfields project located in northwest BC, which is optioned to Eldorado Gold Corporation. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries, please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707.

Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward-looking information under applicable securities laws. Forward-looking information are statements and information that relate to future, not past, events. In this context, forward-looking information often addresses expected future business and financial performance, and often contains words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”; information and statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All information other than information of historical fact included herein are forward-looking information, including, without limitation, information regarding the Company’s business plans and strategies of operations, the Silvergruvan Property and potential for exploration; the Option and TSXV approval of the Option Agreement. By its nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking information is based on management’s beliefs, estimates and opinions on the date that such information is provided and the Company undertakes no obligation to update forward-looking information if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking information.

Link:
https://brixtonmetals.com/wp-content/uploads/2026/09/NR_Figure-1_23Sept2026-scaled.png

Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs

Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities.

MitoCareX is evaluating established, commercially available approaches for obtaining proteins as part of its disciplined effort to broaden the research tools available for its in-vitro activities. The assessment will examine whether these approaches are suitable for MitoCareX’s research requirements and may support greater flexibility as its discovery programs progress.

By assessing additional established approaches for obtaining proteins for controlled in-vitro studies, MitoCareX seeks to broaden its research capabilities while also maintaining flexibility in the advancement of its discovery programs. The evaluation remains at an early stage, and there can be no assurance that any approach under consideration will be adopted or provide the anticipated benefits.

“Evaluating appropriate approaches to obtain proteins is part of our methodical approach to developing reliable in-vitro research capabilities,” said Dr. Alon Silberman, Chief Executive Officer of MitoCareX Bio. “Our goal is to assess tools and methods that may support the quality and consistency of our research while maintaining the flexibility required as our discovery programs progress.”

About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses MitoCareX’s evaluation of additional approaches for obtaining proteins, whether any such approaches are suitable for its research requirements, whether any approach under consideration will be adopted, and the potential of such approaches to enhance access to research materials, increase research flexibility, and support the advancement of MitoCareX’s future in-vitro drug discovery programs. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company’s management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company’s stockholders. No securities were sold in connection with the proposed offering.

The offering was made by Biomea pursuant to a shelf registration statement on Form S-3 (File No. 333-289262) that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 5, 2025 and declared effective by the SEC on August 15, 2025, and a preliminary prospectus supplement that was filed with the SEC on September 22, 2026.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea’s beliefs and expectations regarding the termination of its previously-announced public offering, and uncertainties related to market conditions. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Biomea’s most recent annual report on Form 10-K filed on March 24, 2026 and subsequent quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea’s other filings with the SEC. Any forward-looking statements contained in this press release represent Biomea’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Contact:

Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com

Pilots across North America, Continental Europe and the UK & Ireland set foundation for rollout in 2027

GREENWICH, Conn., Sept. 23, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced global pilots of a new Labor Management System (LMS) designed to enhance workforce planning capabilities and operating efficiencies.

The pilots, being conducted at sites across the U.S., UK, Netherlands, Poland and Spain, represent an important step toward the creation of a standard single global labor management solution that can be deployed consistently across GXO’s operations worldwide.

“We are continuously looking for new ways to help our sites operate more efficiently while delivering even greater value to our customers,” said Bart Beeks, Chief Operations Officer, GXO. “A single global labor management system is a key lever of The GXO Way, our global operations framework for standardizing and scaling operational excellence. A standardized LMS will support more informed decision-making and help us drive productivity at scale. The pilots are an important milestone in building a consistent, data-driven approach to labor management across our operations worldwide.”

The LMS provides real-time visibility into labor performance and workforce planning, helping site leaders better align resources with customer demand while improving operational efficiency. By providing a common platform and standardized performance framework, the LMS will help accelerate operational improvements while supporting GXO’s growth and profitability objectives.

GXO expects to begin scaling the LMS platform across its network in 2027, as part of its broader strategy to standardize best practices, accelerate continuous improvement and strengthen operational excellence across its global footprint.

About GXO

GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has over 150,000 team members across more than 1,000 facilities, totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.

Media contacts
Matthew Schmidt 
+1 203-307-2809 
matt.schmidt@gxo.com

Kathleen Juviler
+1 203-921-9121
Kathleen.juviler@gxo.com

GREAT NECK, N.Y., Sept. 23, 2026 (GLOBE NEWSWIRE) —

Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on July 28, 2026, a cash dividend of $0.11 per share will be paid to all shareholders of record on October 8, 2026. The dividend will be paid on October 15, 2026.

Contact:
Assaf Ran, CEO
(516) 444-3400
www.linkedin.com/in/assafran
SOURCE: Manhattan Bridge Capital, Inc.

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.

EADV Congress 2026 Presentation Details:

Late-Breaker Oral Presentation:

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of the Phase 2 Placebo Controlled LOTUS Trial
Presenter: Dr. Martina Porter, Assistant Professor of Dermatology at Harvard Medical School and Vice Chair for Research and Academics, Department of Dermatology at Beth Israel Deaconess Medical Center
Location: Hall A
Date: Thursday, October 1, 2026 5:00pm CEST

Poster Presentation:

Title: Efficacy and Safety of Abdakibart, a Selective Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa; Primary Results of the Placebo-Controlled Phase 2 LOTUS Trial
Location: ePoster Area; Inflammatory Skin Diseases – Part II
Date: Wednesday, September 30, 2026 7:00am CEST

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Talisker Resources Ltd. (“Talisker”) (TSX: TSK; OTCQX: TSKFF), a junior resource company involved in the exploration and development of gold projects in British Columbia, has qualified to trade on the OTCQX® Best Market. Talisker upgraded to OTCQX from the OTCQB® Venture Market.

Talisker begins trading today on OTCQX under the symbol “TSKFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

As one of the largest holders of mineral claims in British Columbia, Talisker has successfully made the transition from explorer, developer to gold producer with its first producing gold mine, the Mustang Mine transitioned into production in H2 2025. Talisker plans to develop numerous mining centres over the 40km strike length of the company’s 100% owned Bralorne Gold Project with a view to achieve its corporate vision of 200,000 ounces of annual gold production. With a global resource of 3.45M oz of with an average grade in excess of 8 g/t Talisker presents a real gold mining growth opportunity. 

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Terry Harbort, CEO of Talisker stated, “We are pleased to have re-qualified for trading on the OTCQX Market which we anticipate will provide Talisker with wider visibility to the US investment community.”

Trading in non-U.S. North American securities on OTC Markets reached $23.4 billion in the second quarter of 2026, representing an 88.25% increase over Q2 2025. OTC Markets recorded $453.34 billion in total dollar volume in the first half of the year. Canada ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker’s flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is producing at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an advanced stage project with significant exploration potential from an historical high-grade producing gold mine and the Spences Bridge Project where the Company has a significant landholding in the emerging Spences Bridge Gold Belt, and several other early-stage Greenfields projects.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:

OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001

ORKA-001 maintained a favorable safety and tolerability profile through Week 28

52-week EVERLAST-A data for all patients expected in December 2026

16-week EVERLAST-B data expected in 4Q 2026

MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis.

“These Week 28 results, with responses continuing to deepen months after the last dose, point to the incredible potential of ORKA-001,” said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. “With over 70% of patients achieving completely clear skin after just two induction doses and a safety profile consistent with the IL-23 class, ORKA-001 has the potential to redefine the standard of care for psoriasis. We look forward to sharing the full 52-week data later this year.”

“The depth of clearance seen at Week 28, achieved without any dosing beyond Week 4, is remarkable,” said Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine and lead investigator for EVERLAST-A. “To see PASI 100 rates continue to climb over time speaks to the potential of this molecule. The emerging profile of ORKA-001 could offer patients substantial disease control along with very infrequent dosing.”

EVERLAST-A is a randomized, double-blind, placebo-controlled Phase 2a trial evaluating the safety, efficacy, and pharmacokinetics of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The study is being conducted across 26 sites in the United States and Canada and enrolled 84 patients randomized 3:1 to receive 600 mg of ORKA-001 at Week 0 and 4 or matching placebo. Patients who initially received placebo received 600 mg of ORKA-001 at Week 16 and 20. The study continues through Week 52 to assess durability of response, maintenance dosing, and long-term safety.

Efficacy

As previously reported, 63.5% of patients (40 of 63) treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16. Clinical responses continued to deepen through Week 28, six months after the last dose of ORKA-001. PASI 100 response rates increased to 71.4% (45 of 63) and PASI 90 response rates increased to 87.3% (55 of 63) at Week 28. IGA 0/1 response rates were maintained at 84.1% (53 of 63).

Patients who initially received placebo and crossed over blinded to ORKA-001 at Week 16 demonstrated a similar pattern of clinical response to those initially receiving ORKA-001. In this dosing arm, 40.0% (8 of 20) achieved PASI 100 at Week 28 (12 weeks after dosing) compared to 42.9% (27 of 63) of patients in the active arm at the equivalent timepoint.

Safety

ORKA-001 continues to be well tolerated, with a safety profile consistent with the IL-23p19 class. Between Weeks 16-28, the only treatment-emergent adverse event in ≥5% of patients receiving ORKA-001 was upper respiratory tract infection, occurring in 8% (7 of 83) of patients. Two patients experienced serious adverse events, neither deemed drug related: one tibial fracture and one case of prostate adenocarcinoma in a patient with elevated prostate-specific antigen (PSA) at baseline. There continue to be no injection site reactions. No impact of anti-drug antibodies on safety, efficacy, or PK has been observed.

Upcoming Milestones for ORKA-001 

Oruka plans to share longer-term data from EVERLAST-A, including efficacy at Week 52 for all patients, in December 2026. The Company also continues to advance the EVERLAST-B Phase 2b trial of ORKA-001, with data expected during the fourth quarter of 2026. 

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. 

Forward Looking Statements

Certain statements in this press release, other than statements of historical fact, are “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefits, efficacy, safety, tolerability, durability of response and dosing profile of ORKA-001; the potential for ORKA-001 to provide durable disease control with infrequent dosing; the planned conduct, progress, timing and results of the EVERLAST-A and EVERLAST-B trials; and the anticipated timing of clinical data readouts. These forward-looking statements are based on Oruka’s current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements except as required by applicable law. 

Investor Contact:

Alan Lada
(650)-606-7911
alan.lada@orukatx.com